This longitudinal pilot study examined the associations between adriamycin, cyclophosphamide and docetaxel (AC-D) treatment and intestinal microbiota, as well as the associations between the intestinal microbiota, chemotherapy toxicity and tumour response in ER+ and HER2− postmenopausal breast cancer patients. Here, ERBB2 is linked to breast cancer.